RPL30P16

Across TCGA pan-cancer cohorts, RPL30P16 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPL30P16’s most consistent transcriptional readouts.

The strongest signal is observed in esophageal carcinoma (ESCA), where RPL30P16 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL30P16 is over-expressed in tumor, although a few such as ESCA show the opposite, repressed pattern.

ESCA, COAD, and LUSC are the cancer types where RPL30P16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL30P16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
ESCA	All	II,III,IV	−0.155	.001	2	view →
COAD	All	II,III,IV	+0.070	.027	2	view →
LUSC	Male	All	+0.025	.013	1	view →
LIHC	All	All	+0.011	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RPL30P16–ESCA

Open the ESCA breakdown →